Drug and alcohol dependence · 2025
Prescribing of controlled substances to adolescents and young adults enrolled in Medicaid, 2001-2019.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bushnell Greta, Olfson Mark, Lloyd Kristen, Shiau Stephanie, Gerhard Tobias, Keyes Katherine M, Hasin Deborah, Cerdá Magdalena, Samples Hillary
Аннотация
OBJECTIVE: To examine nationwide trends in the prescribing of controlled medications to early adolescents, adolescents, and young adults enrolled in public insurance (Medicaid) from 2001 to 2019.
METHODS: The study utilized US Medicaid data covering publicly insured enrollees from 43 states (2001-2019). Early adolescents (10-12y), adolescents (13-17y), and young adults (18-24y, 25-29y) with ≥ 10 months enrollment in each calendar year were included. Filled prescription for opioids, stimulants, benzodiazepines, Z-hypnotics, barbiturates, and gabapentin were identified. In each calendar year, annual proportions with 1 + controlled medication, 2 + classes of controlled medications, and each controlled medication were estimated.
RESULTS: In 2019, the sample included 17.9 million enrollees (53 % female). The annual proportion prescribed any controlled medication peaked at 17.5 % in early adolescents (2003), 20.6 % in adolescents (2009), and 34.1 % (18-24y) and 47.0 % (25-29y) in young adults (2010). By 2019, the proportions declined to 11.7 % (early adolescents), 12.6 % (adolescents), 16.2 % (18-24y), and 23.9 % (25-29y). Trends varied by medication and age. The largest absolute decline was in the proportion with an opioid filled (2010 =29.8 %, 2019 =11.2 %, young adults 18-24y; 2003 =14.3 %, 2019 =4.4 %, adolescents). In contrast, the proportion with a stimulant fill increased, with eight-fold increases in young adults 25-29y (2001 =0.3 %, 2019 =2.6 %). Benzodiazepine and Z-hypnotic use peaked in 2010 and declined through 2019.
CONCLUSIONS: In the past two decades, there were increases in stimulant prescriptions among young Medicaid enrollees. The declines in opioid, benzodiazepines, barbiturate and Z-hypnotic prescribing are encouraging and may indicate more cautious prescribing related to greater awareness of harms such as misuse and overdose, along with policy initiatives.
METHODS: The study utilized US Medicaid data covering publicly insured enrollees from 43 states (2001-2019). Early adolescents (10-12y), adolescents (13-17y), and young adults (18-24y, 25-29y) with ≥ 10 months enrollment in each calendar year were included. Filled prescription for opioids, stimulants, benzodiazepines, Z-hypnotics, barbiturates, and gabapentin were identified. In each calendar year, annual proportions with 1 + controlled medication, 2 + classes of controlled medications, and each controlled medication were estimated.
RESULTS: In 2019, the sample included 17.9 million enrollees (53 % female). The annual proportion prescribed any controlled medication peaked at 17.5 % in early adolescents (2003), 20.6 % in adolescents (2009), and 34.1 % (18-24y) and 47.0 % (25-29y) in young adults (2010). By 2019, the proportions declined to 11.7 % (early adolescents), 12.6 % (adolescents), 16.2 % (18-24y), and 23.9 % (25-29y). Trends varied by medication and age. The largest absolute decline was in the proportion with an opioid filled (2010 =29.8 %, 2019 =11.2 %, young adults 18-24y; 2003 =14.3 %, 2019 =4.4 %, adolescents). In contrast, the proportion with a stimulant fill increased, with eight-fold increases in young adults 25-29y (2001 =0.3 %, 2019 =2.6 %). Benzodiazepine and Z-hypnotic use peaked in 2010 and declined through 2019.
CONCLUSIONS: In the past two decades, there were increases in stimulant prescriptions among young Medicaid enrollees. The declines in opioid, benzodiazepines, barbiturate and Z-hypnotic prescribing are encouraging and may indicate more cautious prescribing related to greater awareness of harms such as misuse and overdose, along with policy initiatives.